Paris-based biotech startup DeepLife, which builds AI-powered digital twins of cells for biotech and pharma innovation, has secured $10 million in a Series A funding round led by Turenne Groupe and YZR Capital. The funding will support drug discovery advancements and global expansion.
- Founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, DeepLife develops a SaaS platform that leverages generative AI and multi-omics data to create digital twins of cells.
- The platform combines deep learning algorithms with cell atlases to perform in silico simulations, identifying molecular triggers and engineering cell behavior. This accelerates drug discovery, particularly for autoimmune and neurodegenerative diseases.
- DeepLife has shifted its focus from selling cell data to utilizing its genAI platform for molecule development. The company recently secured its first commercial agreements, including a two-year licensing deal with a molecule manufacturer, demonstrating the platform’s ability to deliver results in months rather than years.
Details of the deal
- The Series A round was led by Munich-based health tech venture fund YZR Capital and Turenne Groupe, a venture capital firm based in Paris that supports startups across various sectors, including healthcare, industrial startups, deep tech, and environmental services.
"We are excited to join the company on its mission to accelerate drug discovery and to further expand their footprint from France across Europe and beyond," YZR Capital's team, commented on LinkedIn.
- Hamburg-based Beiersdorf, Groupe Prunay, and existing investors also joined the round.
- DeepLife plans to expand in the US by building technical and sales teams, with a potential full relocation after a Series B round in early 2026. The company will continue advancing its genAI platform, focusing on autoimmune and neurodegenerative diseases, and exploring new uses for existing drugs.
"This achievement is more than a funding round, it’s a testament to the incredible DeepLife team, whose talent, passion, and perseverance are transforming the future of drug discovery," DeepLife's team, stated on LinkedIn.
